Shabina R Ahmed1, Douglas W Ball. 1. Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA.
Abstract
CONTEXT: Medullary thyroid carcinoma (MTC) is diagnosed only after thyroidectomy in approximately 10-15% of cases. This delay in diagnosis can have adverse consequences such as missing underlying pheochromocytoma or hyperparathyroidism in unrecognized multiple endocrine neoplasia type 2 and choosing a suboptimal extent of surgery. Barriers to accurate preoperative diagnosis and management strategies after the discovery of occult MTC are reviewed. EVIDENCE ACQUISITION: We reviewed PubMed (1975-September 2010) using the search terms medullary carcinoma, calcitonin, multinodular goiter, Graves' disease, calcium/diagnostic use, and pentagastrin/diagnostic use. EVIDENCE SYNTHESIS: The combined prevalence of occult MTC in thyroidectomy series is approximately 0.3%. Routine calcitonin measurement in goiter patients identifies C-cell hyperplasia as well as MTC. Challenges include interpreting intermediate values and unavailability of pentagastrin stimulation testing in the United States. Early studies have begun to identify appropriate cutoff values for calcium-stimulated calcitonin. For management of incidentally discovered MTC, we highlight the role of early measurement of calcitonin and carcinoembryonic antigen, RET testing, and comprehensive neck ultrasound exam to direct further imaging, completion thyroidectomy, and lymph node dissection. CONCLUSIONS: Occult MTC is an uncommon, but clinically significant entity. If calcium stimulation testing cutoff data become well-validated, calcitonin screening would likely become more widely accepted in the diagnostic work-up for thyroid nodules in the United States. Among patients with incidental MTC, those with persistently elevated serum calcitonin levels, positive RET test, or nodal disease are good candidates for completion thyroidectomy and lymph node dissection in selected cases, whereas patients with undetectable calcitonin, negative RET testing, and no sonographic abnormalities often may be watched conservatively.
CONTEXT: Medullary thyroid carcinoma (MTC) is diagnosed only after thyroidectomy in approximately 10-15% of cases. This delay in diagnosis can have adverse consequences such as missing underlying pheochromocytoma or hyperparathyroidism in unrecognized multiple endocrine neoplasia type 2 and choosing a suboptimal extent of surgery. Barriers to accurate preoperative diagnosis and management strategies after the discovery of occult MTC are reviewed. EVIDENCE ACQUISITION: We reviewed PubMed (1975-September 2010) using the search terms medullary carcinoma, calcitonin, multinodular goiter, Graves' disease, calcium/diagnostic use, and pentagastrin/diagnostic use. EVIDENCE SYNTHESIS: The combined prevalence of occult MTC in thyroidectomy series is approximately 0.3%. Routine calcitonin measurement in goiterpatients identifies C-cell hyperplasia as well as MTC. Challenges include interpreting intermediate values and unavailability of pentagastrin stimulation testing in the United States. Early studies have begun to identify appropriate cutoff values for calcium-stimulated calcitonin. For management of incidentally discovered MTC, we highlight the role of early measurement of calcitonin and carcinoembryonic antigen, RET testing, and comprehensive neck ultrasound exam to direct further imaging, completion thyroidectomy, and lymph node dissection. CONCLUSIONS: Occult MTC is an uncommon, but clinically significant entity. If calcium stimulation testing cutoff data become well-validated, calcitonin screening would likely become more widely accepted in the diagnostic work-up for thyroid nodules in the United States. Among patients with incidental MTC, those with persistently elevated serum calcitonin levels, positive RET test, or nodal disease are good candidates for completion thyroidectomy and lymph node dissection in selected cases, whereas patients with undetectable calcitonin, negative RET testing, and no sonographic abnormalities often may be watched conservatively.
Authors: Claudia Scollo; Eric Baudin; Jean-Paul Travagli; Bernard Caillou; Nicolas Bellon; Sophie Leboulleux; Martin Schlumberger Journal: J Clin Endocrinol Metab Date: 2003-05 Impact factor: 5.958
Authors: Andreas Machens; Patricia Niccoli-Sire; Josef Hoegel; Karin Frank-Raue; Theo J van Vroonhoven; Hans-Dietrich Roeher; Robert A Wahl; Peter Lamesch; Friedhelm Raue; Bernard Conte-Devolx; Henning Dralle Journal: N Engl J Med Date: 2003-10-16 Impact factor: 91.245
Authors: M Puccini; G Manca; C Ugolini; V Candalise; A Passaretti; J Bernardini; G Boni; P Buccianti Journal: J Endocrinol Invest Date: 2014-06-21 Impact factor: 4.256
Authors: E J Ha; J H Baek; D G Na; J-h Kim; J K Kim; H S Min; D E Song; K E Lee; Y K Shong Journal: AJNR Am J Neuroradiol Date: 2015-04-30 Impact factor: 3.825
Authors: Héctor Vázquez-Lorente; Duško M Dundjerović; Svetislav B Tatić; Sara Rodríguez-Menéndez; Héctor González-Iglesias; Cláudio M Gomes; Ivan R Paunović; Vesna V Dragutinović Journal: Biol Trace Elem Res Date: 2022-09-26 Impact factor: 4.081
Authors: Ayman A Zayed; Moaath K Mustafa Ali; Omar I Jaber; Moh'd J Suleiman; Ashraf A Ashhab; Wajdi Mohammed Al Shweiat; Munther Suliaman Momani; Maha Shomaf; Salah Mohammed AbuRuz Journal: Endocrine Date: 2014-07-24 Impact factor: 3.633
Authors: Marcos R Tavares; Sérgio P A Toledo; Fábio L M Montenegro; Raquel A Moyses; Rodrigo A Toledo; Tomoko Sekyia; Claudio R Cernea; Lenine G Brandão Journal: Clinics (Sao Paulo) Date: 2012 Impact factor: 2.365